Chiao J W, Villalon P, Schwartz I, Wormser G P
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA.
FEMS Immunol Med Microbiol. 2000 Jul;28(3):193-6. doi: 10.1111/j.1574-695X.2000.tb01476.x.
The modulation of human lymphocyte proliferative responses was demonstrated with a recombinant outer surface protein A (OspA) vaccine preparation for the prevention of Borrelia burgdorferi infection. After exposure to either the unaltered vaccine preparation or OspA prepared in saline, normal lymphocyte responses to the mitogens concanavalin A, phytohemagglutinin-M or pokeweed mitogen, or the antigen BCG were consistently reduced. Whole cell extracts of B. burgdorferi also modulated immune responses but required a much greater quantity of protein than needed for the OspA preparation. The magnitude of modulation was directly dependent on the quantity of OspA. OspA interferes with the response of lymphocytes to proliferative stimuli including a blocking of cell cycle phase progression. Future studies designed to delete the particular region or component of the OspA molecule responsible for this effect may lead to improved vaccine preparations.
一种用于预防伯氏疏螺旋体感染的重组外表面蛋白A（OspA）疫苗制剂被证明可调节人类淋巴细胞增殖反应。在暴露于未改变的疫苗制剂或盐水中制备的OspA后，正常淋巴细胞对丝裂原刀豆球蛋白A、植物血凝素-M或商陆有丝分裂原，或抗原卡介苗的反应持续降低。伯氏疏螺旋体的全细胞提取物也可调节免疫反应，但所需的蛋白量比OspA制剂多得多。调节程度直接取决于OspA的量。OspA干扰淋巴细胞对增殖刺激的反应，包括阻断细胞周期阶段进展。旨在删除负责这种效应的OspA分子特定区域或成分的未来研究可能会带来改进的疫苗制剂。
